The effect of vitamin D supplementation on plasma high sensitivity C-reactive protein and P-selectin in patients with thromboembolism

Evaluation of vitamin D supplementation on plasma hs-CRP level and P-selectin in patients with vitamin D deficiency and thromboembolism; A Randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201407048307N7

Enrollment

Registered

2015-04-12

Start date

2014-12-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis. Venous embolism and thrombosis

Interventions

Intervention 1: Intervention group: vitamin D3 oral pearl 50000 international units once a week until 8 weeks, then once every two weeks until 1 month ( a total of 3 months) plus the standard treatmen

Prevention

Control group: give only the standard treatment.

Intervention group: vitamin D3 oral pearl 50000 international units once a week until 8 weeks, then once every two weeks until 1 month ( a total of 3 months) plus the standard treatment.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with confirmed acute thrombosis; vitamin D deficiency; patients with 18 years old and over; consented patients. Exclusion criteria: Hypercalcemia; nephrolithiasis; Sarcoidosis; vitamin D supplementation; malabsorbtion syndrome; Severe infection; uncontrolled autoimmune and inflammatory diseases; pregnancy; drugs and conditions that affect the P-selectin and high sensitivity C-reactive protein levels.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Level of high sensitivity C-reactive protein. Timepoint: Before, 1 month and 3 months after intervention. Method of measurement: ELISA.;Level of P-selectin. Timepoint: Before,1 month and 3 months after intervention. Method of measurement: ELISA.;Level of 25-hydroxy vitamin D. Timepoint: Before, 1 and 3 months after intervention. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Taher Entezari-Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3334 4798

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026